Evidence map›Paper›PMID 41581109›Full record

ReviewStem cell reviews and reports2026

Engineered Extracellular Vesicles for Cancer Stem Cell Theranostics: Recent Advances and Future Perspectives.

Mustafa Abdullah, Waleed K Abdulsahi, Wael Waleed Mustafa, S Renuka Jyothi, Priya Priyadarshini Nayak, J Bethanney Janney, Gurjant Singh, Aashna Sinha, Obid Khamidov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mustafa AbdullahElectric Vehicle Engineering Department, Hourani Center for Applied Scientific Research, Faculty of Engineering, Al-Ahliyya Amman University, Amman, 19328, Jordan.
Waleed K AbdulsahiDepartment of Pharmacology and Toxicology, College of Pharmacy, Al Farahidi University, Baghdad, Iraq. waleedk.abdulsahib@uoalfarahidi.edu.iq.
Wael Waleed MustafaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Turath University College, Baghdad, Iraq.
S Renuka JyothiDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Priya Priyadarshini NayakDepartment of Medical Oncology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India.
J Bethanney JanneyDepartment of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Gurjant SinghDepartment of Physiotherapy, University Institute of Allied Health Sciences, Chandigarh University, Chandigarh State, Punjab, India.
Aashna SinhaSchool of Applied and Life Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, India.
Obid KhamidovDepartment of Medical Radiology, Samarkand State Medical University, Samarkand, Uzbekistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) pose a formidable therapeutic challenge as a treatment-resistant subpopulation that is critical for tumor recurrence and metastasis. A theranostic approach, unifying diagnosis and treatment in a single strategy, presents a viable pathway to overcome this obstacle. This review focuses on engineered extracellular vesicles (EVs), particularly exosomes, as an emerging and flexible platform for CSC theranostics. We examine recent advances in EV engineering that enhance their utility as both sensitive biomarkers for CSC detection and targeted delivery vehicles for anticancer agents. Furthermore, we discuss the development of synthetic EVs designed to counteract the pro‑tumorigenic functions of natural CSC‑derived EVs, which drive angiogenesis, metastasis, and therapy resistance. Finally, we evaluate the translational pathway for EV‑based theranostics, highlighting their significant clinical potential while also highlighting persisting challenges. Engineered EV platforms, by enabling simultaneous diagnosis and treatment, hold considerable promise as they leverage their dual roles as native biomarkers and customizable drug delivery systems.

Indexed as

Extracellular VesiclesNeoplasmsNeoplastic Stem CellsTheranostic NanomedicineAnimalsBiomarkers, TumorExosomesHumansBiomarkers, TumorCancer stem cells (CSCs)Diagnostic potentialExosomesExtracellular vesiclesTheranosticsTherapeutic potential

Identifiers

PMID41581109

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.